Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of divarasib versus sotorasib or adagrasib in previously treated KRAS G12C-positive advanced or metastatic non-small cell lung cancer
jRCT2031240278Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of divarasib, sotorasib and adagrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-Free Survival. Started Oct 2024; status: active, not recruiting.
02
Drugs
divarasibsotorasibadagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240278.